Anika Therapeutics, Inc. (ANIK) financial statements and ratios from SEC XBRL: revenue $112.82M (TTM), net margin -9.6%, revenue growth -5.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $112.82M |
| Net Margin | -9.6% |
| Revenue Growth (YoY) | -5.9% |
| EPS Growth (YoY) | -80.2% |
| FCF Growth (YoY) | -287.1% |
| Price / Book | 2.09 |
| Price / Sales | 2.39 |
| FCF Yield | -7.2% |
| Altman Z-Score | 5.04 (safe) |
| Sector P/E (Healthcare) | 21.6 |
ANIK overview · ANIK earnings · ANIK KPIs · ANIK investor relations · ANIK ownership · ANIK peers · ANIK filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.